Free Trial

Prelude Therapeutics (PRLD) News Today

Prelude Therapeutics logo
$0.82 -0.07 (-7.60%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Prelude Therapeutics Incorporated stock logo
Boxer Capital Management LLC Purchases New Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD)
Boxer Capital Management LLC bought a new stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,708,187 shares of the company's stock, valued at approxima
Prelude Therapeutics Incorporated stock logo
Renaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD)
Renaissance Technologies LLC grew its position in Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) by 222.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 634,500 shares of the compan
Prelude Therapeutics Incorporated stock logo
JMP Securities Reaffirms "Market Outperform" Rating for Prelude Therapeutics (NASDAQ:PRLD)
JMP Securities reaffirmed a "market outperform" rating and issued a $4.00 target price on shares of Prelude Therapeutics in a research report on Tuesday.
Prelude Therapeutics Incorporated stock logo
Prelude Therapeutics (PRLD) Projected to Post Quarterly Earnings on Tuesday
Prelude Therapeutics (NASDAQ:PRLD) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-prelude-therapeutics-incorporated-stock/)
Prelude Therapeutics Founder Acquires 28% More Stock
Prelude Therapeutics CEO buys $467K in common stock
Barclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
Prelude Therapeutics sees cash runway into 2Q26
Prelude Therapeutics Incorporated stock logo
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires $12,000.00 in Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CEO Krishna Vaddi bought 10,000 shares of the business's stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $1.20 per share, with a total value of $12,000.00. Following the purchase, the chief executive officer now directly owns 137,553 shares of the company's stock, valued at approximately $165,063.60. This represents a 7.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Prelude Therapeutics Incorporated stock logo
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Acquires $82,200.00 in Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) insider Andrew Combs purchased 60,000 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $1.37 per share, with a total value of $82,200.00. Following the transaction, the insider now directly owns 377,623 shares in the company, valued at approximately $517,343.51. This trade represents a 18.89 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics
Prelude Therapeutics Incorporated stock logo
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Acquires $22,750.00 in Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CFO Bryant David Lim purchased 25,000 shares of Prelude Therapeutics stock in a transaction dated Thursday, December 19th. The stock was bought at an average price of $0.91 per share, with a total value of $22,750.00. Following the acquisition, the chief financial officer now directly owns 27,400 shares of the company's stock, valued at approximately $24,934. This trade represents a 1,041.67 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Prelude Therapeutics Incorporated stock logo
Krishna Vaddi Buys 100,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CEO Krishna Vaddi purchased 100,000 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The stock was acquired at an average price of $0.93 per share, for a total transaction of $93,000.00. Following the purchase, the chief executive officer now owns 1,167,275 shares of the company's stock, valued at approximately $1,085,565.75. This represents a 9.37 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Prelude Therapeutics (PRLD) Gets a Sell from Morgan Stanley
Prelude Therapeutics presents first interim data from trial of PRT2527
Prelude Therapeutics price target lowered to $4 from $7 at JMP Securities
Prelude Therapeutics Incorporated stock logo
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,940,000 shares, a growth of 18.1% from the October 15th total of 2,490,000 shares. Currently, 13.9% of the shares of the company are sold short. Based on an average trading volume of 340,700 shares, the short-interest ratio is presently 8.6 days.
Prelude Therapeutics (PRLD) Receives a Sell from Barclays
Prelude Therapeutics Incorporated stock logo
Prelude Therapeutics' (PRLD) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research report on Friday.
Prelude Therapeutics Shows Strong Q3 2024 Financial Results
Prelude Therapeutics Incorporated stock logo
Prelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research note on Monday.
Prelude Therapeutics price target lowered to $1 from $3 at Barclays
Get Prelude Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.

PRLD Media Mentions By Week

PRLD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PRLD
News Sentiment

0.45

0.72

Average
Medical
News Sentiment

PRLD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PRLD Articles
This Week

11

1

PRLD Articles
Average Week

Get Prelude Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:PRLD) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners